-- Julie Rubinstein, President and Chief Operating Officer, on April 17, 2026, sold 69,061 shares in Adaptive Biotechnologies (ADPT) for $1,008,622. Following the Form 4 filing with the SEC, Rubinstein has control over a total of 395,146 common shares of the company, with 395,146 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1478320/000178066426000028/xslF345X05/form4.xml